Lithium Augmentation in Treatment-Resistant Depression: Clinical Evidence, Serotonergic and Endocrine Mechanisms

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Bschor, T ^a   Lewitzka, U ^a   Sasse, J ^b   Adli, M ^b   Koberle U ^b   Bauer, M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antidepressant; Augmentation; DEX CRH test; Lithium; Major depression; Serotonin; Treatment resistant depression

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE; LITHIUM SALT; PLACEBO; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; NEUROTRANSMISSION; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIPOLAR DISORDER; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LITHIUM COMPOUNDS; PITUITARY-ADRENAL SYSTEM; SEROTONIN;

EID: 0347003602     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Adli M, Berghöfer A, Linden M, Helmchen H, Müller- Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry 2002; 63: 782-790
2. Adli M, Bschor T, Canata B, Döpfmer S, Bauer M. Lithium in the treatment of acute depression [Article in German]. Fortschr Neurol Psychiatr 1998; 66: 435-441
3. Álvarez E, Pérez-Solá V, Pérez-Blanco J, Queraltó JM, Torrubia R, Noguera R. Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord 1997; 42: 179-186
4. Amsterdam JD, Winokur A, Abelman E, Lucki I, Rickels K. Cosyntropin (ACTH alpha 1-24) stimulation test in depressed patients and healthy subjects. Am J Psychiatry 1983; 140: 907-909
5. Barden N, Reul JM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995; 18: 6-11
6. Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Bschor T. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiat 2003; 48: 440-446
7. Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435
8. Bauer M, Forsthoff A, Baethge C, Adli M, Berghöfer A, Döpfmer S, Bschor T. Lithium augmentation therapy in refractory depression - Update 2002. Eur Arch Psychiatry Clin Neurosci 2003; 253: 132-139
9. Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434
10. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 2002; 3: 5-43
11. Bauer M. The combined use of lithium and SSRIs. J Serotonin Res 1995; 2: 69-76
12. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-314
13. Blier P, Montigny de C. Short-term lithium administration enhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS. Eur J Pharmacol 1985; 133: 66-77
14. Browne M, Lapierre YD, Hrdina PD, Horn E. Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol 1990; 5: 103-110
15. Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacol 2002; 27: 470-478
16. Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M. Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiat Res 2003; 37: 135-143
17. Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 2003; 17: 43-48
18. Bschor T, Berghöfer A, Ströhle A, Kunz D, Adli M, Müller-Oerlinghausen B, Bauer M. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002; 22: 427-430
19. Bschor T, Canata B, Müller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disorders 2001; 64: 261-265
20. Chaput Y, Montigny de C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991; 5: 219-229
21. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-1734
22. Cowen PJ, McCance SL, Ware CJ, Cohen PR, Chalmers JS, Julier DL. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 1991; 159: 341-346
23. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999; 60: 142-156
24. Dinan TG. Psychoneuroendocrinology of mood disorders. Curr Opin Psychiatry 2001; 14: 51-55
25. Dinan TG. Neuroendocrinology of mood disorders. Curr Opin Psychiatry, 1997; 10: 84-87
26. Fieve RR, Peselow ED. Lithium: clinical applications. In Burrows GD, editor. Psychiatry Series Amsterdam: Elsevier, 1994: pp. 277-321
27. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983; 280: 176-179
28. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 1983; 40: 1335-1342
29. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996; 153: 93-99
30. Holsboer F, Lauer Ch J, Schreiber W, Krieg JC. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995; 62: 340-347
31. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacol 2000; 23: 477-501
32. Huang X, Wu DY, Chen G, Manji H, Chen DF. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci 2003; 44: 347-354
33. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992; 72: 165-229
34. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163: 574-578
35. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387-393
36. Kantor D, McNevin S, Leichner P, Harper D, Krenn M. The benefit of lithium carbonate adjunct in refractory depression - fact or fiction? Can J Psychiatry 1986; 31: 416-418
37. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Burns RA, Robertson MM. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80-86
38. Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000; 61 (suppl 9): 5-15
39. Maes M, Meltzer HY. The serotonin hypotheses of major depression. In Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progess New York: Raven Press, 1995: 933-944
40. Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351
41. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 2001; 178 (suppl 41): 107-119
42. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, Zarate CA Jr, Charney DS. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-742
43. McCance-Katz E, Price LH, Charney DS, Heninger GR. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 1992; 108: 93-97
44. Montigny de C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978; 202: 1303-1306
45. Montigny de C, Cournoyer G, Morisette R. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antideoressant drugs and lithium on the serotonin system. Arch Gen Psychiatry 1983; 40: 1327-1334
46. Montigny de C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-256
47. Montigny de C. Lithium addition in refractory depression. In Nolen WA, Zohar J, Roose SP, Amsterdam JD, editors. Refractory Depression: Current Strategies and Future Directions London: John Wiley & Sons, Ltd, 1994: 47-57
48. Montigny de C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol 1994; 9 (suppl 2): 31-35
49. Montigny de C. Lithium addition in treatment-resistant depression: evidence for the involvement of the serotonin system. In Racagni G, Brunello N, Fukuda T, editors. Biological Psychiatry; Volume 1 Amsterdam: Elsevier Science Publishers B.V., 1991: 243-244
50. Müller-Oerlinghausen B. Lithium long-term treatment - does it act via serotonin? Pharmacopsychiatry 1985; 18: 214-217
51. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986; 143: 363-366
52. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry 1998; 59 (suppl 16): 13-19
53. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress Anxiety 1996; 4: 169-181
54. Okamoto Y, Motohasi N, Hayakawa H, Muraoka M, Yamawaki S. Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex. Neuropsychobiology 1996; 33: 17-20
55. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer"s disease amyloid-beta peptides. Nature 2003; 423: 435-439
56. Platman SR, Fieve RR. Lithium carbonate and plasma cortisol response in the affective disorders. Arch Gen Psychiatry 1968; 18: 591-594
57. Platman SR, Hilton JG, Koss MC, Kelly WG. Production of cortisol in patients with manic-depressive psychosis treated with lithium carbonate. Dis Nerv Syst 1971; 32: 542-544
58. Price LH, Carpenter LL, Rasmussen SA. Drug combination strategies. In Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-resistant mood disorders Cambridge: University Press, 2001: 194-222
59. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 459-472
60. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology (Berl) 1990; 100: 3-12
61. Price LH, Charney DS, Henninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986; 143: 1387-1392
62. Reisine T, Zatz M. Interactions among lithium, calcium, diacylglycerides, and phorbolesters in the regulation of adrenocorticotropin hormone release from AtT-20 cells. J Neurochem 1987; 49: 884-889
63. Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998; 59 (suppl 5): 32-39
64. Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 1992; 2: 161-165
65. Schatzberg AF, Garlow SJ, Nemeroff CB. Molecular and cellular mechanisms in depression. In Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology Philadelphia: Lippincott Williams & Wilkins, 2002: 1039-1050
66. Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989; 22: 183-187
67. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry 1999; 60 (suppl 4): 57-61
68. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158: 666-675
69. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-640
70. Sugawara M, Hashimoto K, Hattori T, Takao T, Suemaru S, Ota Z. Effects of lithium on the hypothalamo-pituitary-adrenal axis. Endocrinol Jpn 1988; 35: 655-663
71. Thase ME, Rush AJ. Treatment-resistant depression. In Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress New York: Raven Press, 1995: 1081-1097
72. Torres G, Horowitz JM, Laflamme N, Rivest S. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neuroscience 1998; 87: 463-477
73. Wegener G, Bandpey Z, Heiberg IL, Mork A, Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology (Berl) 2003; 166: 188-194
74. Zatz M, Reisine TD. Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells. Proc Natl Acad Sci USA 1985; 82: 1286-1290
75. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001; 34: 119-127
76. Zusky PM, Biederman J, Rosenbaum JF, Manschreck TC, Gross CC, Weilberg JB, Gastfriend DR. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988; 8: 120-124